Fig. 5: Among patients with ctDNA positivity during the MRD window, ctDNA clearance is associated with superior DFS compared to no ctDNA clearance.
From: ctDNA-based molecular residual disease and survival in resectable colorectal cancer
a,b, Kaplan–Meier estimates for DFS (a) and OS (b) stratified by ctDNA clearance status from MRD window to 3-month timepoint in MRD-positive patients receiving ACT. This analysis was landmarked at the date of 3-month timepoint. P = 2.67 × 10−16 (a). Two-sided chi-square test for bar plot: P = 4.65 × 10−10 (a). c,d, Kaplan–Meier estimates for DFS (c) and OS (d) stratified by ctDNA clearance status from MRD window to 6-month timepoint in MRD-positive patients receiving ACT. P = 4.24 × 10−15 (c). Two-sided chi-square test for bar plot: P = 3.62 × 10−9 (c). HRs and 95% CIs were calculated using the Cox proportional hazard model. P values were calculated using the two-sided log-rank test. This analysis was landmarked at the date of 6-month timepoint. Analyses were performed using R software version 4.4.0. Median DFS and percentage DFS at 24 months were estimated from the landmark timepoint.
